By now you've seen post-ASCO QuickPolls in melanoma and GU cancers, and in between we ran a blog on some recent compelling clinical news in NSCLC. Following up on the NSCLC news, we think it is a good time to present QuickPoll outcomes in NSCLC. QuickPolls are a first glimpse into physicians’ reactions to new data presented at ASCO ’11. OBR and MDoutlook are pleased to share results from MDoutlook’s 4th annual post-ASCO survey fielded among its global network of 52,000 cancer physicians.
Quick Poll Methodology and Respondents’ Geographic Distribution
1) NSCLC Treaters Plan Increased Usage of Erlotinib While Decreasing Usage of Platinum Based Chemotherapy
2) Large Proportion of Clinicians Plan to Always Use Crizotinib EML4-ALK+ NSCLC patients
3) Anti-c-Met Combination Therapy is Expected to Have a Positive Impact on Treatment of c-Met+ Patients
4) Screening of NSCLC Patients for c-Met Mutation is Expected to Increase Dramatically in the Near Future
Quick polls are a fast way of measuring expected acceptance of clinical data post major medical meetings, and perhaps can be used to make some assumptions about adoption amongst providers. In today’s information hungry environment, the speed at which these polls can be conducted and analyzed can be advantageous for market planning and “pressure testing” acceptance of data amongst key stakeholders.
You must be logged in to post a comment